Developer of new medicines that have breakthrough potential in treating inflammatory disease and cancer.
June 2005: seed £0.75m
June 2007: first round post-seed £0.85m
Dec 2008: second round post-seed £1.08m
April 2010 October 2012: series of smaller rounds £2.08m
June 2012: Series B investment, First Tranche £4.85m full amount not disclosed.
Total raised so far: £9.6m plus undisclosed tranches of the Series B
"We were based at SETsquared for several years. It was an excellent, cost-effective environment to develop the company. Having people around from SETsquared to call on for advice and assistance was terrifically helpful."
"We took part in the SETsquared investor readiness programme, which helped us to secure investments,
and also put us directly in contact with angel investment groups."
"Through SETsquared, we took part in the Connect programme with the University of California.SETsquared provided a mentor to help us prepare, and to manage the relationships we built."
"We also participated in the Investment Showcase. This brought us into contact with potential investors, and helped us understand what they were looking for."
"Our large Series B investment wasn't out of the blue: building blocks had been created over many years, a number which were due to SETsquared's help."Simon Kerry, CEO, Karus Therapeutics